Market Performance Overview
Vivos Therapeutics (ticker VVOS) concluded the trading session on Friday, 23 October 2026, at 12:10 AM Central Europe with a decline of 4.26 % relative to the previous close. The share price settled at USD 0.13, a value that is readily accessible on major electronic exchanges. At this price, the outstanding supply of 20.1 million shares corresponds to a market capitalization of USD 2.8 million.
During the 24‑hour window, roughly USD 622.2 k of the company’s shares were transacted, indicating a moderate level of liquidity. Over the past month, the share price has slipped 14.01 %, underscoring a period of downward pressure that has outpaced the broader market movement in the same sector.
A 200‑day simple moving average of Vivos Therapeutics sits at USD 0.81, a figure that lies well above the current price, suggesting that the stock is trading below a historically averaged valuation. The most recent 52‑week high, USD 3.1, was recorded on 24 October 2025, while the 52‑week low of USD 0.12 was observed on 20 October 2026, highlighting a significant volatility corridor for the share.
Comparative Peer Activity
For context, the performance of related biopharmaceutical and medical‑technology stocks over the same 24‑hour period is as follows:
| Symbol | Company | 24‑Hour Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| GRI | Gri Bio | +0.68 % | USD 1.42 | USD 3.2 million |
| CVKD | Cadrenal Therapeutics | –1.92 % | USD 0.97 | USD 3.2 million |
| AIDX | 20/20 Biolabs | 0 % | USD 0.25 | USD 3.4 million |
| CCHH | Cch | 0 % | USD 0.90 | USD 3.3 million |
| NCRA | Nocera | +1.36 % | USD 1.42 | USD 3.1 million |
These figures illustrate that Vivos Therapeutics’ decline is part of a broader sectoral softness, though the magnitude of the fall remains notable relative to its peers.
Company Background
Vivos Therapeutics, Inc. is a medical‑technology firm headquartered in Highlands Ranch, United States, and listed on the Nasdaq stock exchange. The company is dedicated to the development of innovative solutions for patients suffering from sleep disordered breathing and obstructive sleep apnea. Its portfolio focuses on technologies that aim to improve respiratory function during sleep, thereby enhancing overall patient quality of life. Operations and sales are confined to the United States, and the firm continues to pursue research and development initiatives that align with its mission to transform sleep‑related respiratory care.
For further information, investors and stakeholders may consult the company’s official website at www.vivoslife.com .
